RNXT

Healthcare Biotechnology

RenovoRx, Inc.

$1.58

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

71.30M

Avg Volume

744,604

EPS

-$0.31

52W High

$2.59

52W Low

$0.70

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-13.17

P/B Ratio

7.94

P/S Ratio

36.09

EV/EBITDA

-4.77

EV/Revenue

31.49

Margins

Gross Margin 84.4%

Operating Margin (368.4%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

115.4%

Return on Equity

(125.2%)

Return on Assets

(64.9%)

Liquidity & Leverage

Current Ratio

5.74

Quick Ratio

5.29

Debt / Equity

0.04

Total Cash

9.48M

Total Debt

390,000

About

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

renovorx.com